Other News To Note
Wednesday, June 19, 2013
Civitas Therapeutics Inc., of Chelsea, Mass., said it received a $1 million grant from the Michael J. Fox Foundation for Parkinson's Research to support a Phase IIb trial of CVT-301, an inhaled formulation of levodopa that is being developed as an adjunct therapy to provide rapid relief from intermittent debilitating motor fluctuations, known as "off" episodes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.